Story · Medicine & Biotech
Belzutifan Plus Lenvatinib Moves Closer to EU Approval for Advanced Kidney Cancer
1 outlet · first reported by OncoDaily on
A new combination treatment for advanced kidney cancer has moved one step closer to European approval. Merck has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for (OncoDaily)
Coverage, in order
-
Belzutifan Plus Lenvatinib Moves Closer to EU Approval for Advanced Kidney CancerA new combination treatment for advanced kidney cancer has moved one step closer to European approval. Merck has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.